CoChat

Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke)

Open access
Yaghi, Shadi, Furie, Karen L., Viscoli, Catherine M., Kamel, Hooman, Gorman, Mark, Dearborn, Jennifer, Young, Lawrence H., Inzucchi, Silvio E., Lovejoy, Anne M., Kasner, Scott E., Conwit, Robin, Kernan, Walter N. · 2018 · Circulation
Cited by 64

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Background: The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone reduced the risk for a composite outcome of stroke or myocardial infarction among nondiabetic patients with insulin resistance and a recent stroke or transient ischemic attack. The current planned secondary analysis uses updated 2013 consensus criteria for ischemic stroke to examine the effect of pioglitazone on stroke outcomes. Methods: Participants were randomly assigned to receive pioglitazone (45 mg/d target dose) or placebo within 180 days of a qualifying ischemic stroke or transient ischemic attack and were followed for a maximum of 5 years. An independent committee, blinded to treatment assignments, adjudicated all potential stroke outcomes. Time to first stroke event was compared by treatment group, overall and by type of event (ischemic or hemorrhagic), using survival analyses and Cox proportional hazards models. Results: Among 3876 IRIS participants (mean age, 63 years; 65% male), 377 stroke events were observed in 319 participants over a median follow-up of 4.8 years. Pioglitazone was associated with a reduced risk for any stroke at 5 years (8.0% in comparison with 10.7% for the placebo group; hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.60–0.94; log-rank P =0.01). Pioglitazone reduced risk for ischemic strokes (HR, 0.72; 95% CI, 0.57–0.91; P =0.005) but had no effect on risk for hemorrhagic events (HR, 1.00; 95% CI, 0.50–2.00; P =1.00). Conclusions: Pioglitazone was effective for secondary prevention of ischemic stroke in nondiabetic patients with insulin resistance. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00091949.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.117.030458

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

Metadata

Authors
Yaghi, S., Furie, K. L., Viscoli, C. M., Kamel, H., Gorman, M., Dearborn, J., Young, L. H., Inzucchi, S. E., Lovejoy, A. M., Kasner, S. E., Conwit, R., & Kernan, W. N.
Venue
Circulation
Published
2018-01-30
Volume
137
Issue
5
Pages
455-463
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2765128406
Cited by
64
References
10
FWCI
3.71
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.